SBIR-STTR Award

VP22 Mediated Delivery of Protein and DNA into Cells
Award last edited on: 6/5/08

Sponsored Program
SBIR
Awarding Agency
NIH : NIMH
Total Award Amount
$850,633
Award Phase
2
Solicitation Topic Code
-----

Principal Investigator
Robert P Bennett

Company Information

Life Technologies (AKA: Invitrogen Corporation)

5791 Van Allen Way
Carlsbad, CA 92008
   (760) 603-7200
   tech_service@invitrogen.com
   www.invitrogen.com
Location: Multiple
Congr. District: 49
County: San Diego

Phase I

Contract Number: 1R43MH057611-01
Start Date: 00/00/00    Completed: 00/00/00
Phase I year
1997
Phase I Amount
$99,849
This proposal outlines the development of a system to introduce peptides into mammalian tissue culture cells in a rapid and efficient manner. This system utilize a 16 amino acid peptide, derived from the Drosophilia Antennapedia homeoprotein, that is translocated across neuronal membranes when incubated extracellularly. Internalization of this peptide does not appear to be mediated by endocytosis or require a receptor, suggesting that it may be useful in a variety of cell types. A prokaryotic expression vector win he constructed for cost-efficient synthesis and purification of Antennapedia fusion peptides. Translocation of peptide fusions of different sizes will be tested to determine the steric constraints of this system. The translocation of these peptides will also be tested with many common tissue culture cell lines to prove the utility of this technology. Unlike techniques requiring direct injection of peptides into cells, introduction of this peptide vector into cells is rapid and efficient. Once internalized, this peptide is found in both the cytoplasm and nucleus. This technology has a wide variety of applications, including the delivery of inhibitory or therapeutic peptides, the delivery of oligonucleotides, and gene therapy. PROPOSED COMMERCIAL APPLICATION: Phase I research will result in a prokaryotic plasmid vector that allows simple expression and purification of Antennapedia peptide fusions. These peptides can be used to introduce peptides or oligonucleotides into cells quickly and efficiently. The Antennapedia technology can he applied to research in many disciplines, including gene transfer and gene therapy.

Thesaurus Terms:
DNA binding protein, biotechnology, chimeric protein, transfection, transfection vector Drosophilidae, method development, oligonucleotide, peptide structure, protein sequence, protein transport PC12 cell, prokaryote, protein purification, tissue /cell cultureNational Institute of Mental Health (NIMH)

Phase II

Contract Number: 2R44MH057611-02
Start Date: 00/00/00    Completed: 00/00/00
Phase II year
1999
(last award dollars: 2000)
Phase II Amount
$750,784

This proposal outlines the development of VP22 as a delivery vehicle for protein and DNA molecules to cells in culture. The Phase I proposal demonstrated the power of protein-mediated delivery by expressing and purifying protein fusions with the Antennapedia peptide from E. coli. These fusion proteins were translocated across biological membranes, accumulating in the cytoplasm and nucleus. A new translocating protein, VP22, was recently described and has two significant advantages over the Antennapedia peptide: 1) VP22 can translocate larger peptides and 2) expression of VP22 in a subpopulation of cells results in spread of the protein throughout the entire culture. During the Phase II period, prokaryotic and eukaryotic vectors for the expression and purification of VP22 fusion proteins will be constructed. VP22 fusions will be used to develop systems that can regulate gene expression. VP22 fusions that interact with DNA will be developed and used to investigate the ability of VP22 to deliver oligonucleotides and plasmid DNA to cells in culture. This revolutionary technology has broad applications for the delivery of proteins and DNA to cells that cannot be transfected with current technologies and will provide new techniques to study gene function in all cell types. PROPOSED COMMERCIAL APPLICATIONS: Prokaryotic and eukaryotic vectors will be constructed to allow researchers to express and purify VP22 fusion proteins. VP22 fusions will be constructed to develop an inducible gene expression system and to deliver single chain antibodies to intracellular targets. Reagents based on VP22 will be developed for the delivery of oligonucleotides and plasmid DNA to tissue culture cells that are refractory to current transfection technologies